|By PR Newswire||
|August 28, 2014 10:00 AM EDT||
CAMBRIDGE, Mass., Aug. 28, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, announced today that Dr. David Cook, Seres' Executive Vice President of R&D and Chief Scientific Officer, will be presenting at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The presentation will highlight the scientific and medical implications of SER-109, a novel mixture of bacterial spores derived from the human microbiome, and provide final data on Seres' single-arm, open-label clinical trial of SER-109.
The presentation is scheduled for Monday, September 8, 2014, from 3:00 p.m. – 5:30 p.m. ET in meeting room 151B at the Walter E. Washington Convention Center in Washington, DC. Dr. Cook's presentation will be part of the session "Clostridum difficile: Pathogenesis, Immune Response and Therapy."
SER-109 is the lead Seres Health Ecobiotic® microbial therapeutic in clinical testing for the treatment of recurrent Clostridium difficile infection (CDI). SER-109 was developed utilizing the Seres Health Microbiome Therapeutics™ platform that provides deep insight into the ecologies of disease and then identifies microbial compositions that can catalyze a shift to health. CDI is a rapidly growing problem associated with antibiotic use. Approximately 100,000 - 150,000 of CDI patients in the U.S. have more than one recurrence. Multiple recurrent CDI has recently been designated as an Orphan Drug Indication by the FDA.
About Seres Health
Seres Health is a clinical-stage therapeutics company focused on discovering and developing Ecobiotic® therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. Founded by Flagship VentureLabs™, Seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. Current candidates span infectious, metabolic, and inflammatory diseases. Seres recently announced a research agreement with Mayo Clinic and has received over $20 million in funding to date. For more information, please visit www.sereshealth.com.
For Seres Health: Emily Rossi
SOURCE Seres Health
Aug. 27, 2016 07:45 AM EDT Reads: 734
Pulzze Systems was happy to participate in such a premier event and thankful to be receiving the winning investment and global network support from G-Startup Worldwide. It is an exciting time for Pulzze to showcase the effectiveness of innovative technologies and enable them to make the world smarter and better. The reputable contest is held to identify promising startups around the globe that are assured to change the world through their innovative products and disruptive technologies. There w...
Aug. 27, 2016 07:45 AM EDT Reads: 612
Aug. 27, 2016 06:15 AM EDT Reads: 2,330
Aug. 27, 2016 03:15 AM EDT Reads: 1,763
Aug. 27, 2016 02:30 AM EDT Reads: 1,999
Aug. 27, 2016 01:45 AM EDT Reads: 1,729
Aug. 27, 2016 01:30 AM EDT Reads: 2,091
Aug. 27, 2016 01:15 AM EDT Reads: 2,009
Aug. 27, 2016 12:45 AM EDT Reads: 2,930
Aug. 27, 2016 12:45 AM EDT Reads: 2,150
Aug. 27, 2016 12:15 AM EDT Reads: 2,288
Aug. 26, 2016 10:45 PM EDT Reads: 2,072
Aug. 26, 2016 10:00 PM EDT Reads: 1,857
Aug. 26, 2016 09:15 PM EDT Reads: 1,442
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
Aug. 26, 2016 07:15 PM EDT Reads: 443